Switch theme
Sign up to access all valuation multiples
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
2018
18
LTM Revenue $14.0M
Last FY EBITDA -$57.5M
$14.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Opus Genetics has a last 12-month revenue (LTM) of $14.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Opus Genetics achieved revenue of $11.0M and an EBITDA of -$57.5M.
Opus Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Opus Genetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.0M | XXX | $11.0M | XXX | XXX | XXX |
| Gross Profit | $13.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$57.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -523% | XXX | XXX | XXX |
| EBIT | -$51.7M | XXX | -$34.1M | XXX | XXX | XXX |
| EBIT Margin | -370% | XXX | -310% | XXX | XXX | XXX |
| Net Profit | -$48.1M | XXX | -$57.5M | XXX | XXX | XXX |
| Net Margin | -344% | XXX | -523% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Opus Genetics's stock price is $1.
Opus Genetics has current market cap of $56.1M, and EV of $14.3M.
See Opus Genetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.3M | $56.1M | XXX | XXX | XXX | XXX | $-1.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Opus Genetics has market cap of $56.1M and EV of $14.3M.
Opus Genetics's trades at 1.3x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Opus Genetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Opus Genetics has a P/E ratio of -1.2x.
See valuation multiples for Opus Genetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56.1M | XXX | $56.1M | XXX | XXX | XXX |
| EV (current) | $14.3M | XXX | $14.3M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOpus Genetics's last 12 month revenue growth is 40%
Opus Genetics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $2.5M for the same period.
Opus Genetics's rule of 40 is -13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Opus Genetics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Opus Genetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -523% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -13% | XXX | -483% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 244% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 410% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opus Genetics acquired XXX companies to date.
Last acquisition by Opus Genetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Opus Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Opus Genetics founded? | Opus Genetics was founded in 2018. |
| Where is Opus Genetics headquartered? | Opus Genetics is headquartered in United States of America. |
| How many employees does Opus Genetics have? | As of today, Opus Genetics has 18 employees. |
| Who is the CEO of Opus Genetics? | Opus Genetics's CEO is Dr. George Magrath, PhD. |
| Is Opus Genetics publicy listed? | Yes, Opus Genetics is a public company listed on NAS. |
| What is the stock symbol of Opus Genetics? | Opus Genetics trades under IRD ticker. |
| When did Opus Genetics go public? | Opus Genetics went public in 2020. |
| Who are competitors of Opus Genetics? | Similar companies to Opus Genetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Opus Genetics? | Opus Genetics's current market cap is $56.1M |
| What is the current revenue of Opus Genetics? | Opus Genetics's last 12 months revenue is $14.0M. |
| What is the current revenue growth of Opus Genetics? | Opus Genetics revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Opus Genetics? | Current revenue multiple of Opus Genetics is 1.0x. |
| Is Opus Genetics profitable? | Yes, Opus Genetics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
